Sirolimus (Rapamycin or Rapamune ) , Blood

Sirolimus (Rapamycin) inhibits clinical allogeneic transplantation responses, including graft rejection and graft versus host disease (GVHD). However, rapamycin therapy is limited by systemic toxicity and
lack of single-agent efficacy. The molecular mechanism of action of rapamycin involves mammalian target of rapamycin (mTOR) inhibition, which in turn reduces mRNA translation, protein phosphorylation and cell cycle progression. Because signalling through mTOR is critical for homeostasis in immune and non-immune cells, mTOR inhibition in vivo represents a relatively non-specific immune modulation approach. Immunologically, rapamycin mediates immunosuppression by blocking cytokine, mitogenic, and accessory signal responsiveness but not cytokine production. Therefore, it may be particularly useful in the early post-BMT period in which alloreactivity may be driven by the release of cytokines from non-T-cell populations.

Monitoring sirlolimus blood levels is used to maintain a therapeutic dose and avoid drug-induced toxicity.

2 ml EDTA Whole Blood Room Temperature

4- 20 ng/ml